New therapeutic targets, such as the aforementioned selective Sphk2 inhibitors potentially affecting WT1 gene expression and reducing proteinuria [17,39], as well as innovative strategies like stem cell therapy [40], highlight promising directions for future research into the treatment of nephropathy associated with WT1 pathogenic variants. Here, SPHK2 is linked to kidney disorder.